Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy-Reference-Cited by-同舟云学术

Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy

Published:2003-08-06 Issue:3 Volume:107 Page:434-440
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Saint Fabien,Kurth Nathalie,Maille Pascale,Vordos Dimitri,Hoznek Andre,Soyeux Pascale,Patard Jean Jacques,Abbou Claude C.,Chopin Dominique K.

Funder

INSERM EMI 03-97

Fondation de l'Avenir pour la Recherche Médicale Appliquée

Fondation pour la Recherche Médicale

Université Paris XII

AP-HP Hôpitaux de Paris

Association Claude Bernard

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference43 articles.

1. Intracavity bacillus Calmette-Guérin in the treatment of superficial bladder tumors;Morales;J Urol,1976

2. Experience with intravesical bacillus Calmette-Guérin therapy of superficial bladder tumors;Herr;Urology,1989

3. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study;Lamm;J Urol,2000

4. Tolerability of bacillus Calmette-Guérin maintenance therapy for superficial bladder cancer;Saint;Urology,2001

5. Interleukin-8 expression in the urine after bacillus Calmette-Guérin therapy: a potential prognostic factor of tumor recurrence and progression;Thalmann;J Urol,1997

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type 2 innate lymphoid cells are not involved in mouse bladder tumor development;Frontiers in Immunology;2024-01-12

2. Value of Immunological Biomarkers in Early Prediction of Bacillus Calmette-Guerin Failure in High-Risk Non-muscle-invasive Bladder Cancer;annals of urologic oncology;2023-10-05

3. The past, present, and future of immunotherapy for bladder tumors;Medical Oncology;2022-09-29

4. Immune status for monitoring and treatment of bladder cancer;Frontiers in Immunology;2022-09-08

5. Elevated T-cell exhaustion and urinary tumor DNA levels are associated with BCG failure in patients with non-muscle invasive bladder cancer;2022-03-23